Share

    


In This Section

Immunomedics Announces New C-Code for Trodelvy™, Effective October 2020

Immunomedics announced the new C-Code (C-9066) for Trodelvy™ (sacituzumab govitecan-hziy), effective October 2020. Trodelvy is indicated for the treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease.

C-codes are used primarily to report services under the Outpatient Prospective Payment System (OPPS), but may also be recognized by other private and public payer types. Please check with each payer for specific requirements.

Find out more on billing and coding for Trodelvy on its website.

Posted 10/15/2020